Stock 600511 CHINA NATIONAL MEDICINES CORPORATION LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News China National Medicines Corporation Ltd.

Equities

600511

CNE000001D56

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 25/04/2024 BST 		5-day change 1st Jan Change
34.94 CNY +0.32% Intraday chart for China National Medicines Corporation Ltd. -2.35% +22.08%
04-25 China National Medicines Corporation Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-21 China Stocks Muted at Close as Recovery Optimism Fades; Sinopharm Jumps 6% on Upbeat 2023 Earnings MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
China National Medicines Corporation Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
China Stocks Muted at Close as Recovery Optimism Fades; Sinopharm Jumps 6% on Upbeat 2023 Earnings
MT
Sinopharm's 2023 Profit Climbs 9%; Shares Up 6%
MT
China National Medicines Corporation Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
China National Medicines Deputy Manager Under Probe for Alleged Insider Trading
MT
CASI Pharmaceuticals, Inc. Enters into an Exclusive Distribution Agreement with China National Medicines Corporation Ltd
CI
China National Medicines' Profit Drops 16.1% in Q3
MT
China National Medicines Corporation Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Sinopharm CFO Retires; Successor Named
MT
China National Medicines Corporation Ltd.(XSSC:600511) added to S&P Global BMI Index
CI
China National Medicines Corporation Ltd.(XSSC:600511) added to FTSE All-World Index
CI
China National Medicines' Profit Climbs 14.2% in H1
MT
China National Medicines Corporation Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
China National Medicines' Q1 Profit Rises 10.9%
MT
China National Medicines Corporation Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Sinopharm’s Profit Rises 12% in 2022; Revenue Slips 2%
MT
China National Medicines' 2022 Profit Up 12%
MT
Sinopharm Eyes Production of Merck's COVID-19 Drug in China
MT
Sinopharm Clarifies It Is Not A Distributor for Pfizer's COVID-19 Drug
MT
Sinopharm to Buy $168 Million Shares in Shyndec Pharma
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 600511 Stock
  4. News China National Medicines Corporation Ltd.